HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 8,100 shares, a decline of 67.5% from the October 15th total of 24,900 shares. Based on an average trading volume of 27,600 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the shares of the company are short sold.

HCW Biologics Stock Performance

HCWB stock traded down $0.04 during midday trading on Tuesday, hitting $0.32. 1,241,993 shares of the stock traded hands, compared to its average volume of 25,830. The stock’s fifty day simple moving average is $0.51 and its 200-day simple moving average is $0.72. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.10 and a quick ratio of 0.10. HCW Biologics has a 1-year low of $0.30 and a 1-year high of $1.93. The firm has a market cap of $11.95 million, a P/E ratio of -0.35 and a beta of 0.83.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter. HCW Biologics had a negative return on equity of 385.90% and a negative net margin of 978.03%. The business had revenue of $0.62 million during the quarter.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.